Home > News > Chiesi to Present Data at the American Thoracic...

Autorizzo al trattamento dei miei dati personali
ai sensi del D.L. 30 giugno 2003 n. 196
Edit email address
Invalid email
Your request has been sent successfully
Authorize the processing of personal data

Chiesi to Present Data at the American Thoracic Society Conference

Date: 17/05/2024

Eight abstracts from Chiesi’s global respiratory research portfolio will be presented at the American Thoracic Society (ATS) 2024 International Conference in San Diego starting from May 17, 2024. Presentations include preclinical and clinical stage global studies in asthma, Chronic Obstructive Pulmonary Disease (COPD) and other respiratory conditions.


“Chiesi’s Air franchise has a robust history spanning multiple decades of delivering innovative medicines in Europe, and we’re excited to share some of the research supporting our global scientific advancements in the respiratory therapeutic area at ATS," said Carmen Dell’Anna, Head of Global Medical Affairs, Chiesi Group. "Alongside updates on our scientific progress, the Chiesi expert-led Innovation Hub will focus on discussing the role of small airway dysfunction and persistent airflow limitation in asthma. With a solid presence at the ATS conference this year, we affirm our distinctive commitment to address respiratory-related burdens by focusing on creating shared value for people and the planet.”


Demonstrating the company’s commitment to innovation, Chiesi is a Sapphire level sponsor of the annual ATS Research Program Benefit. Chiesi is also sponsoring a one-year research grant for a respiratory disease researcher to advance the understanding of obstructive lung disease.


Chiesi Foundation will also participate in the conference with a session titled "Global Health Inequities in Chronic Respiratory Disease: Challenges and Potential Solutions." Chaired by Dr. Mario Scuri, MD, PhD, GASP Technical Advisor at Chiesi Foundation, the session will feature renowned speakers, including Dr. William Checkley, Dr. Laura Nicolaou, and Dr. Robert D. Levy.


Chiesi’s US respiratory business continues growing since, on May 6, 2024, it signed a license agreement with Gossamer Bio to develop and commercialize seralutinib. The collaboration leverages Chiesi's leadership in inhaled drugs and Gossamer Bio's expertise in pulmonary hypertension with the goal of addressing conditions with high unmet medical need